SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Hyperliquid is a performant L1 optimized from the ground up. The vision is a fully onchain open financial system with user built applications interfacing with performant native components, all without compromising end user experience. The Hyperliquid L1 is performant enough to operate an entire ecosystem of permissionless financial applications – every order, cancel, trade, and liquidation happens transparently on-chain with block latency <1 second. The chain currently supports 100k orders / second. The Hyperliquid L1 uses a custom consensus algorithm called HyperBFT which is heavily inspired by Hotstuff and its successors. Both the algorithm and networking stack are optimized from the ground up to support the L1. The flagship native application is a fully onchain order book perpetuals exchange, the Hyperliquid DEX. Further developments include a native token standard, spot trading, permissionless liquidity, etc.

Hype

Hype is trending as users discuss its potential for growth and efficiency, with some touting it as a top-tier coin with a possible U.S. launch. Community members are also excited about the recent launch of an AI trading bot on the platform and the potential for significant price movement, while others are debating its suitability as a treasury asset.

Ozarus is an AI-powered on-chain intelligence platform built on Solana, designed to protect traders and communities from scams, rugpulls, and high-risk tokens. The platform scans thousands of tokens daily, providing real-time risk scores, security audits, and token reliability insights. Its mission is to make Solana’s ecosystem safer, transforming trading from speculation-driven chaos into a transparent, data-backed environment.

Ozarus

Ozarus Crypto is trending as the community discusses its potential as "the evolution of strength" and "the rise of the alpha". Traders are pointing to accumulation patterns, suggesting a possible imminent move, and drawing comparisons to other popular cryptocurrencies.

VanEck ETF Trust - VanEck Uranium Nuclear Energy ETF

VanEck Uranium Nuclear Energy ETF

The VanEck Uranium Nuclear Energy ETF ($NLR) is trending as the community discusses nuclear energy's potential role in powering the AI boom and meeting increasing electricity demands, highlighting infrastructure and policy considerations. Some traders are noting technical patterns and potential breakout levels, while others are cautioning against hype and advocating for profit-taking given the sector's volatility. The ETF's exposure to uranium miners, reactors, and power operators is also a key discussion point.

An AI x Metaverse Protocol that is building the future of virtual interactions.

Virtual Protocol

Virtual Protocol is trending as community members highlight its AI integration and potential in the play-to-earn and virtual world sectors, with some suggesting its technology bridges blockchain with gaming, creating tokenized economies. Chatter suggests the project's recent price action and rising volumes are attracting attention, while others point to its growing ecosystem and new exchange listings as potential catalysts. Community members are also actively discussing various AI agents built on the platform.

The Real FartCoin as suggested by Truth Terminal, following the "FartCoin Launch Strategy". Full FartCoin Ecosystem with a major focus on Planting Trees across the world.  FartNFTs,FartDAO,FartSwap and many other applications are part of our movement. With the also correct Token Mechanics such as the correct Ticker, Supply, Blockchain and Purpose of the token.  Community ran and funded, with great intentions to follow up with the full "lore" of the FartCoin!

FartCoin

FartCoin is trending as traders discuss its potential amid the current meme coin frenzy, with some pointing to its low market cap and potential for significant gains. Community members are comparing it to other popular meme coins, speculating whether it will be the next big mover in the crypto space. The coin is also being discussed in relation to other trending cryptos, with some users suggesting it could ignite an 'alt season'.

What is the project about? Pepe is a community based meme token surround the iconic meme Pepe the frog. Pepe aims to leverage the power of such an iconic meme to become the most memeable memecoin in existence.   What makes your project unique? Pepe is here to make memecoins great again. Ushering in a new paradigm for memecoins, Pepe represents the memecoin in it's purest simplicity. With zero taxes, liquidity locked forever, and contract immutable, Pepe is for the people, forever. Pepe is about culture, rallying together a community to have fun and enjoy memes, fueled purely by memetic power.   History of your project. Pepe was stealth launched on Friday, April 14th, 2023.   What’s next for your project? Pepe will focus on developing a tight-knit community around the token and building resources to enrich the communities knowledge and success in crypto through a token gated group, newsletter, and more tools.   What can your token be used for? Pepe can be used to speculate on the power of memes, and does not pretend to be anything more.

Pepe

PEPE is seeing active discussion around potential for a trend reversal, with community members assessing dip-buying opportunities and comparing it to other meme coins. Some traders are closely watching its chart patterns for signals of a breakout, while others express frustration with recent price action. The community also mentions a few other meme coins that could see similar success to PEPE.

What Is Tezos (XTZ)?   Tezos is a high-performing blockchain and open-source platform for assets and applications, with a strong focus on code security, on-chain governance, and decentralization. Tezos 2.0, the upcoming step in the evolution of Tezos, aims to improve scalability (via layer 2s), composability, and to implement support to mainstream programming languages (like Javascript, Typescript, Python, and many others).   Initially built with formal verification in mind, the Tezos protocol enables builders to avoid bugs when developing smart contracts, making it particularly suited to applications that require a high degree of security and certainty.   Tezos’ LPoS (Liquid Proof-of-Stake) consensus mechanism enables any stakeholder to take part, directly or by delegation, in the consensus process, and to be rewarded for securing the network. Rather uniquely, Tezos’ on-chain governance system also enables stakeholders to create and vote on protocol upgrade proposals. This pioneering system allows the protocol to self-amend and upgrade itself without leading to a split (or fork) in the blockchain, empowering the community without slowing down innovation.   First proposed in 2014 and launched in 2018, the Tezos Mainnet has a proven track record of running uninterrupted ever since, having earned a strong reputation for technical excellence and a supportive community.    Who Are the Founders of Tezos? Tezos was conceived by Arthur and Kathleen Breitman in a 2014 white paper under the pseudonym L.M. Goodman in a nod to Satoshi Nakamoto, referencing a journalist who had misidentified the creator of Bitcoin.   In a previous paper, the Breitmans had argued that Bitcoin's biggest shortcomings were the lack of a governance process that invited contributions from its community of users, cost and centralization issues raised by its proof-of-work system, the limited expressiveness of its programming language which didn’t allow for smart contracts, and security

Tezos

Tezos is trending with community members actively debating its potential and future price movement. Discussions range from bullish perspectives citing strong fundamentals and governance to bearish sentiment emphasizing concerns about its circulating supply. The launch of Sugar Match on Tezos' Etherlink is also being noted.

Rigel Pharmaceuticals, Inc. operates as a clinical stage biotechnology company. It discovers and develops novel, targeted drugs in the therapeutic areas of immunology, oncology and immune oncology. The firm focuses on intracellular signalling pathways and related targets that are critical to disease mechanisms. The company's products include Tavalisse, Fostamatinib and R835. Rigel Pharmaceuticals was founded by Donald G. Payan, James M. Gower, Thomas A. Raffin, Garry P. Nolan and Ronald B. Garren on June 14, 1996 and is headquartered in South San Francisco, CA.

Rigel Pharmaceuticals

RIGL is trending due to its high short interest and potential for a short squeeze, with the community closely watching upcoming earnings and patent news. Community members are discussing the company's low PE ratio and analysts suggesting it may be undervalued, contributing to bullish sentiment. Recent news of insider options and a presentation by the CEO have further fueled speculation of a potential acquisition.

Vanguard Group, Inc. - Vanguard S&P 500 ETF

Vanguard S&P 500 ETF

VOO is trending as investors analyze market behavior ahead of potential Federal Reserve decisions, with some highlighting the ETF's consistent long-term growth potential. Discussions also include commentary on high valuations and signals from chart analysis. Some community members are exiting positions in other assets and consolidating portfolios into VOO for stability.

Ford Motor Co. engages in the manufacture, distribution, and sale of automobiles. It operates through the following segments: Ford Blue, Ford Model E, Ford Pro, Ford Next, Ford Credit, and Corporate Other. The Ford Blue, Ford Model E, and Ford Pro segment includes the sale of Ford and Lincoln vehicles, service parts, and accessories, together with the associated costs to develop, manufacture, distribute, and service the vehicles, parts, and accessories. The Ford Next segment is involved in the expenses and investments for emerging business initiatives aimed at creating value for Ford in vehicle-adjacent market segments. The Ford Credit segment consists of the Ford Credit business on a consolidated basis, which is primarily vehicle-related financing and leasing activities. The Corporate Other segment refers to corporate governance expenses, past service pension and OPEB income and expense, interest income and gains and losses from cash, cash equivalents, and marketable securities, and foreign exchange derivatives gains, and losses associated with intercompany lending. The company was founded by Henry Ford on June 16, 1903 and is headquartered in Dearborn, MI.

Ford Motor Co.

Ford Motor Co

Ford is trending amid reports of a fire at a key aluminum supplier, potentially impacting F-150 production and future earnings, while the community debates the extent of the disruption and potential for a quick recovery or alternative sourcing; some traders are also eyeing potential tariff relief and upcoming earnings as potential catalysts, while some express concern about lowered guidance and production cuts.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>Retail chatter around Avalo rose ahead of an Oppenheimer conference call set to discuss its lead hidradenitis suppurativa drug, AVTX-009, now in a mid-stage trial with topline results expected in 2026.</li><li>Analysts at H.C. Wainwright, Oppenheimer, TD Cowen, and Cantor Fitzgerald maintain bullish views on Avalo, with price targets ranging from $25 to $35 and expectations that AVTX-009 could outperform AbbVie’s rival therapy.</li><li>On Stocktwits, sentiment turned ‘extremely bullish’ as message activity surged; users highlighted fresh opportunities and long-term upside.</li></ul>Shares of Avalo Therapeutics gained 0.4% in premarket trading on Wednesday amid upbeat investor sentiment ahead of an Oppenheimer analyst call focused on its lead drug candidate, AVTX-009, for hidradenitis suppurativa.&nbsp;The stock is currently trading at a nearly 18-month high.&nbsp;<h2 class="st-heading-2">Pipeline And Trial Progress</h2>Earlier this month, Avalo said it had dosed the first patient in the LOTUS study. The randomized, double-blind, placebo-controlled trial is testing two dosing regimens of AVTX-009, with top-line results expected in 2026.The study’s primary endpoint is the proportion of patients achieving HiSCR75, a 75% reduction in abscess and nodule count at week 16, while secondary measures include HiSCR50 and HiSCR90 response rates, improvements in skin pain and lesion severity, and safety outcomes.AVTX-009 targets interleukin-1β, a cytokine involved in the inflammatory cascade driving HS and several other autoimmune diseases. The drug’s mechanism builds on clinical validation seen with other IL-1 inhibitors and aims to deliver higher potency and longer durability.<h2 class="st-heading-2">Analyst Views&nbsp;</h2>Avalo has drawn attention from multiple brokerages since restarting its HS program this year.In September, H.C. Wainwright raised its price target on Avalo Therapeutics to $25 from $15 and reiterated a ‘Buy’ rating, saying AbbVie’s latest hidradenitis suppurativa data validated the IL-1 pathway but capped efficacy at 45%–50% HiSCR75.Earlier that month, Oppenheimer recommended investors be buyers of Avalo shares ahead of lutikizumab’s open-label Phase 2 data, forecasting “strong results” and expecting AVTX-009, with multiple advantages over lutikizumab, to deliver “at least as good as, and potentially better, efficacy” when LOTUS trial results&nbsp;are read out in mid-2026. The firm maintained an ‘Outperform’ rating and a $35 price target.Separately, TD Cowen initiated coverage with a ‘Buy’ rating, citing AVTX-009’s Phase 2 study in hidradenitis suppurativa and highlighting the high unmet need in a heterogeneous patient population, estimating over $1 billion sales potential.&nbsp;Cantor Fitzgerald also began coverage with an ‘Overweight’ rating, describing Avalo as a clinical-stage biotech focused on autoimmune diseases and noting that AVTX-009, an IL-1N2 antibody, is expected to have a mid-2026 readout.<h2 class="st-heading-2">Stocktwits Traders See Long-Term Upside</h2>On Stocktwits, retail sentiment for Avalo was ‘extremely bullish’ amid a 20% surge in 24-hour message volume.One user noted that the setup still offered opportunities and encouraged others to stay tuned.<stembedurl>https://stocktwits.com/topstockalerts/message/632967338</stembedurl>Another user suggested that Avalo looked like a strong buy and could deliver twentyfold returns for investors willing to hold long term.<stembedurl>https://stocktwits.com/WallGoodman/message/632883343</stembedurl><a href="https://stocktwits.com/symbol/AVTX">Avalo’s stock</a> has more than doubled so far in 2025.For updates and corrections, email newsroom[at]stocktwits[dot]com.

Avalo’s stock has more than doubled so far in 2025. (Photo credit: Getty Images)

Avalo Therapeutics Stock Rises Premarket Ahead Of Oppenheimer Call On Lead Hidradenitis Drug

Retail chatter around Avalo rose ahead of an Oppenheimer conference call set to discuss its lead hidradenitis suppurativa drug, AVTX-009, now in a mid-stage trial with topline results expected in 2026.

Equity

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors

Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry Executive June Almenoff, M.D., Ph.D. to its Board of Directors Actinium Pharmaceuticals Appoints Accomplished Biopharma Industry...

The Lustgarten Foundation Appoints Two New Board Members

The Lustgarten Foundation Appoints Two New Board Members The Lustgarten Foundation Appoints Two New Board Members PR Newswire WOODBURY, N.Y., June 13, 2024 Richard Barakat, MD, and Aaron Kantoff join...

Avalo Therapeutics' Newly Acquired Ex-Eli Lilly Drug Could Stand Out In Competitive Hidradenitis Suppurativa Market, Analyst Upgrades

Unlock the potential of Avalo Therapeutics with AVTX-009, a promising drug for hidradenitis suppurativa. Oppenheimer upgrades to Outperform, foreseeing Phase 2 progress and market distinction...

Avalo Therapeutics Appoints Biotech Leaders to Board of Directors

Appointments include industry veterans Aaron Kantoff, Jonathan Goldman, and Samantha Truex as Independent DirectorsBoard of Director appointments in conjunction with Avalo's recent acquisition of...

Avalo Therapeutics (AVTX) stock slips after earnings: buy the dip?

Avalo Therapeutics (AVTX) stock price nosedived on Monday after the company published relatively weak financial results. It tumbled by over 23.5% in the pre-market session and reached a low of...

Avalo Therapeutics EPS of -$114.00, revenue of $1.92M beats by $0.72M

Avalo Therapeutics EPS of -$114.00, revenue of $1.92M beats by $0.72M...

Avalo Reports 2023 Financial Results and Provides Business Updates

Acquired AVTX-009, Phase-2 ready anti-IL-1 mAb, in March 2024Increased cash position with private placement financing in March 2024 providing up to $185 million, including initial upfront investment...

12 titres de soins de sant  en mouvement lors de la pr -ouverture le 29/03/2024

Gagnants
Le titre Avalo Therapeutics (NASDAQ:AVTX) a mont vendredi de 289,05% 18,48 dollars lors de la session pre-market.
Le titre Xilio Therapeutics (NASDAQ:XLO) a grimp de 205,16% 1,95...

12 titoli sanitari in movimento, pre-market del 29/03/2024

Titoli in rialzo
Le azioni di Avalo Therapeutics (NASDAQ:AVTX) sono cresciute del 289,05% a 18,48 dollari durante la sessione pre-market di venerd .
Il titolo Xilio Therapeutics (NASDAQ:XLO) salito...

Avalo Therapeutics, Inc. is a clinical stage biotechnology company, which engages in the treatment of immune dysregulation by developing therapies that target the LIGHT-signaling network. It also focuses on reducing LIGHT levels which can moderate immune dysregulation in many acute and chronic inflammatory disorders. The company was founded by Blake M. Paterson, Isaac Blech, Barbara S. Slusher, and Solomon H. Snyder on January 31, 2011 and is headquartered in Wayne, PA.

Avalo Therapeutics Inc

Cut 25 bps

Cut 50+ bps

No change

What will the Fed decide at its October meeting? Polymarket gives a 92% chance of a 25 bps cut. 
 
*Powered by Polymarket

AVTX
Avalo Therapeutics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest AVTX News

AVTXAvalo Therapeutics Inc